Just caught something interesting about Disc Medicine that's worth paying attention to. While the stock's been swinging pretty hard lately, a major hedge fund just dropped $52 million into a fresh 650,000-share position in Q4. That kind of conviction move tells you something.

Here's what makes this notable: BVF established this stake before the FDA's Complete Response Letter hit in February, and well before that brutal 20% one-day selloff. So this wasn't some panic-driven rebound trade. The thesis was built on the actual science and the company's balance sheet strength.

Looking at their portfolio, Disc Medicine now sits at about 1.74% of their 13F AUM. It's not in their top five holdings, but it fits a clear pattern - they're concentrated in differentiated biotech names with binary catalysts. Their biggest positions are Kymera, Revolution Medicines, MoonLake, and a couple others in that $240-430M range.

The FDA's feedback was specific: they acknowledged the drug lowered PPIX in EPP patients, but said the existing data didn't prove clinical correlation strongly enough. The real catalyst now is the Phase 3 APOLLO trial, with topline data expected in Q4. If it hits, management's eyeing a potential FDA decision by mid-2027.

What's reassuring for long-term holders? Disc ended 2025 with roughly $791 million in cash and securities, giving them runway into 2029. That's serious runway for a clinical-stage biotech. So the investment thesis has clearly stretched out - you're now betting on APOLLO data and the company's ability to stay funded through commercialization.

The stock's been swinging on FDA uncertainty, which is normal for biotech. But a fund like this doesn't typically add $52 million to a position on a whim. They're betting the thesis timeline just shifted, not that it broke.